+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Gene Therapy Market by Vector Type (Nonviral Vectors, Viral Vectors), Therapy Type (Ex Vivo, In Vivo), Indication, Stage, End User - Global Forecast 2025-2030- Product Image
Cancer Gene Therapy Market by Vector Type (Nonviral Vectors, Viral Vectors), Therapy Type (Ex Vivo, In Vivo), Indication, Stage, End User - Global Forecast 2025-2030- Product Image
Sale

Cancer Gene Therapy Market by Vector Type (Nonviral Vectors, Viral Vectors), Therapy Type (Ex Vivo, In Vivo), Indication, Stage, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010618
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer gene therapy market is experiencing rapid transformation as targeted genomic interventions begin to redefine oncology care. This report distills critical trends, regulatory shifts, and technology drivers, providing senior decision-makers a foundation for strategic investment and operational alignment within this high-growth therapeutic sector.

Market Snapshot: Cancer Gene Therapy Market Overview

The Cancer Gene Therapy Market grew from USD 2.75 billion in 2024 to USD 3.30 billion in 2025. It is projected to maintain robust momentum at a CAGR of 19.45%, targeting USD 8.00 billion by 2030. This upward trajectory reflects accelerated adoption of precision treatments, ongoing clinical successes, and a global push for more patient-specific oncology solutions. Strong investment and regulatory clarity further fuel expansion, positioning the market as a cornerstone within the evolving landscape of cancer therapeutics.

Scope & Segmentation

  • Vector Types: Nonviral vectors such as lipid nanoparticles, polymeric nanoparticles, and physical methods; viral vectors including adeno-associated, adenoviral, lentiviral, and retroviral platforms.
  • Therapy Types: Ex vivo therapies involving cell modification outside the body and in vivo approaches for direct gene delivery within patients.
  • Indications: Hematological cancers (leukemia, lymphoma, myeloma) and solid tumors (breast, colorectal, lung, prostate cancer).
  • Developmental Stages: Preclinical, clinical (phases I to III), and commercial product designations.
  • End Users: Hospitals and clinics, oncology centers, and research laboratories.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the UK, Germany, France, UAE, South Africa, and additional countries), and Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, and more).
  • Technologies: Genome editing with CRISPR-Cas, digital health platforms for patient stratification, modular and single-use manufacturing solutions, and both viral and nonviral delivery systems.
  • Leading Companies: Gilead Sciences, Novartis AG, Bristol-Myers Squibb, Amgen, bluebird bio, Adaptimmune Therapeutics, Cellectis, uniQure, Transgene SA, Sorrento Therapeutics.

Key Takeaways

  • Precision oncology is moving gene therapy into mainstream cancer management, enabling durable and personalized interventions for previously untreatable malignancies.
  • Adoption is driven by advancements in vector engineering, sophisticated manufacturing, and deeper understanding of tumor biology, fueling rapid clinical progression.
  • Regulatory landscapes are maturing, providing clearer approval pathways and motivating companies to accelerate late-stage development and global trials.
  • Nonviral delivery technologies and ex vivo engineering are gaining ground, offering alternatives that may address current manufacturing and supply chain challenges.
  • Regional disparities persist; North America leads in innovation, while Asia-Pacific is seeing accelerated approvals and expanded clinical trial participation mid significant infrastructure growth.
  • Strategic alliances, M&A, and supply diversification are critical for navigating competitive shifts and building long-term resilience in commercialization efforts.

Tariff Impact: Navigating US Trade Adjustments

Recent United States tariff measures on cancer gene therapy inputs have increased manufacturing costs by affecting sourcing of raw materials, viral vectors, and specialized bioprocessing equipment. Stakeholders are actively reassessing procurement strategies, investing in domestic production, and accelerating adoption of alternative delivery modalities to manage these cost pressures. Companies equipped with modular platforms and geographically diverse operations are best positioned to sustain growth and minimize risks from future trade fluctuations.

Methodology & Data Sources

This report leverages a comprehensive methodology integrating secondary research—such as peer-reviewed publications, clinical registry data, and regulatory filings—with primary insights from key opinion leaders, senior executives, and industry experts. Data triangulation and independent validation ensure accuracy and actionable clarity for decision-makers.

Cancer Gene Therapy Market: Why This Report Matters

  • Enables executives to anticipate regulatory, technological, and policy changes that could impact development timelines and commercialization strategies.
  • Provides evidence-based recommendations for optimizing supply chains, managing operational risks, and pursuing high-potential therapeutic opportunities.
  • Empowers teams with insights into emerging competitive landscapes and evolving customer needs, enhancing strategic planning and investment prioritization.

Conclusion

This report equips leaders with the knowledge to align investments, manage risk, and capitalize on innovation in cancer gene therapy. By synthesizing competitive, scientific, and regulatory trends, it supports informed action in a rapidly advancing market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. CRISPR-based multiplexed gene editing strategies refining CAR-T cell persistence in solid tumor treatments
5.2. Nanoformulated lipid nanoparticle carriers enabling in vivo targeted delivery of therapeutic genes to tumor tissue
5.3. Development of oncolytic viral vectors expressing immunomodulatory cytokines to enhance tumor eradication
5.4. Integration of AI-driven bioinformatics for personalized neoantigen identification in gene therapy vaccine design
5.5. Emergence of automated closed-system manufacturing platforms accelerating GMP production of viral gene therapy vectors
5.6. Strategic alliances between biotech innovators and CDMOs streamlining clinical translation of cancer gene therapies
5.7. Expanding regulatory frameworks supporting expedited approval pathways for novel gene therapy oncology treatments
5.8. Advances in multiplexed base editing techniques to correct oncogenic point mutations in solid tumor cells in situ
5.9. Deploying multi-modal combination therapies coupling gene therapy with immune checkpoint blockade to overcome tumor resistance mechanisms
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Gene Therapy Market, by Vector Type
8.1. Introduction
8.2. Nonviral Vectors
8.2.1. Lipid Nanoparticles
8.2.2. Physical Methods
8.2.3. Polymeric Nanoparticles
8.3. Viral Vectors
8.3.1. Adeno-Associated
8.3.2. Adenoviral
8.3.3. Lentiviral
8.3.4. Retroviral
9. Cancer Gene Therapy Market, by Therapy Type
9.1. Introduction
9.2. Ex Vivo
9.3. In Vivo
10. Cancer Gene Therapy Market, by Indication
10.1. Introduction
10.2. Hematological Cancers
10.2.1. Leukemia
10.2.2. Lymphoma
10.2.3. Myeloma
10.3. Solid Tumors
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Lung Cancer
10.3.4. Prostate Cancer
11. Cancer Gene Therapy Market, by Stage
11.1. Introduction
11.2. Clinical Trials
11.2.1. Phase I
11.2.2. Phase II
11.2.3. Phase III
11.3. Commercial
11.4. Preclinical
12. Cancer Gene Therapy Market, by End User
12.1. Introduction
12.2. Hospitals And Clinics
12.3. Oncology Centers
12.4. Research Laboratories
13. Americas Cancer Gene Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cancer Gene Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cancer Gene Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Gilead Sciences, Inc.
16.3.2. Novartis AG
16.3.3. Bristol-Myers Squibb Company
16.3.4. Amgen Inc.
16.3.5. bluebird bio, Inc.
16.3.6. Adaptimmune Therapeutics plc
16.3.7. Cellectis S.A.
16.3.8. uniQure N.V.
16.3.9. Transgene SA
16.3.10. Sorrento Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CANCER GENE THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CANCER GENE THERAPY MARKET: RESEARCHAI
FIGURE 26. CANCER GENE THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 27. CANCER GENE THERAPY MARKET: RESEARCHCONTACTS
FIGURE 28. CANCER GENE THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 131. CANADA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 132. CANADA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 133. CANADA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 136. CANADA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 137. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 138. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 139. CANADA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 142. CANADA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 143. CANADA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 144. CANADA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 145. CANADA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 146. CANADA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 147. CANADA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 148. CANADA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 149. CANADA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. CANADA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. MEXICO CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 152. MEXICO CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 153. MEXICO CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. MEXICO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. MEXICO CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 166. MEXICO CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 167. MEXICO CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. GERMANY CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 254. GERMANY CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 255. GERMANY CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 256. GERMANY CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 257. GERMANY CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 258. GERMANY CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 259. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 260. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 261. GERMANY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. GERMANY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. GERMANY CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 264. GERMANY CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 265. GERMANY CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 268. GERMANY CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 269. GERMANY CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 270. GERMANY CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 271. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. FRANCE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 274. FRANCE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 275. FRANCE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 276. FRANCE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 277. FRANCE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 278. FRANCE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 279. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 280. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 281. FRANCE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. FRANCE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. FRANCE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 284. FRANCE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 285. FRANCE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 286. FRANCE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 288. FRANCE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 289. FRANCE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 290. FRANCE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 291. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 309. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 310. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 311. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. ITALY CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 314. ITALY CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 315. ITALY CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 316. ITALY CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 317. ITALY CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 318. ITALY CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 319. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 320. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 321. ITALY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. ITALY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. ITALY CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
TABLE 324. ITALY CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2030 (USD MILLION)
TABLE 325. ITALY CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 326. ITALY CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 327. ITALY CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 328. ITALY CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 329. ITALY CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 330. ITALY CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 331. ITALY CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. ITALY CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. SPAIN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 334. SPAIN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 335. SPAIN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 336. SPAIN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 337. SPAIN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 338. SPAIN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 339. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 340. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 341. SPAIN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-20

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Gene Therapy market report include:
  • Gilead Sciences, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • bluebird bio, Inc.
  • Adaptimmune Therapeutics plc
  • Cellectis S.A.
  • uniQure N.V.
  • Transgene SA
  • Sorrento Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 8 Billion
Compound Annual Growth Rate19.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cell & Gene Therapy Clinical Trials Market by Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Products), Vector Type (Non-Viral Vector, Viral Vector), Cell Type, Indication, Trial Phase - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Clinical Trials Market by Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Products), Vector Type (Non-Viral Vector, Viral Vector), Cell Type, Indication, Trial Phase - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-Cell Lymphoma, Multiple Myeloma), By Vector Type (Lentivirus, RetroVirus & Gamma RetroVirus, AAV), By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-Cell Lymphoma, Multiple Myeloma), By Vector Type (Lentivirus, RetroVirus & Gamma RetroVirus, AAV), By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Viral Vector Manufacturing Market by Vector Type (Adenoviral Vectors, Baculoviral Vectors, Herpes Simplex Vectors), Workflow (Downstream Processing, Upstream Processing), Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast 2025-2030 - Product Image

Viral Vector Manufacturing Market by Vector Type (Adenoviral Vectors, Baculoviral Vectors, Herpes Simplex Vectors), Workflow (Downstream Processing, Upstream Processing), Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Gene Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Gene Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 124 Pages
  • Global
From

About the Cancer Gene Therapy Market

The Cancer Gene Therapy market is a subset of the larger Genomics market, which focuses on the study of genes and their functions. Cancer Gene Therapy is a form of treatment that uses genetic material to treat or prevent cancer. It involves introducing genetic material into cells to modify their behavior, such as to stop the growth of cancer cells or to make them more sensitive to chemotherapy. This type of therapy has the potential to be more effective and less toxic than traditional treatments. Cancer Gene Therapy is still in its early stages of development, but it has the potential to revolutionize cancer treatment. It is being studied in clinical trials and is expected to become more widely available in the future. Companies in the Cancer Gene Therapy market include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Allergan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.